Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its product RP-A501, leading to inflated stock prices and subsequent investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals made positive statements while concealing serious adverse events, including participant deaths, related to RP-A501 [5]. - The company allegedly amended the trial protocol without informing shareholders, which contributed to the misleading nature of the information provided [5]. Group 2: Investor Information - Investors who purchased Rocket Pharmaceuticals securities during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent the class in the lawsuit [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations, resulting in a significant stock price decline [1][2]. Group 1: Allegations and Financial Impact - The class period for the allegations against Vestis Corporation is from May 2, 2024, to May 6, 2025 [2]. - The complaint states that Vestis provided overly positive statements while concealing material adverse facts about its business growth capabilities, particularly its inability to execute strategic initiatives aimed at improving customer experience and retention [2]. - Following the announcement of disappointing financial results for Q2 2025 and the withdrawal of revenue guidance, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 8, 2025, to potentially become lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Commitment - The Gross Law Firm is dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. due to allegations of misleading statements regarding the company's production capacity and contract values, which have led to significant investor losses [2][4]. Group 1: Company Overview - Red Cat Holdings, Inc. (NASDAQ: RCAT) is involved in the production of small, portable drones for military applications, specifically under the U.S. Army's Short Range Reconnaissance Program [5]. - The company has faced scrutiny for overstating the production capacity of its Salt Lake City facility and the overall value of its contracts, particularly the SRR Contract [4][6]. Group 2: Financial Performance and Stock Impact - Following disclosures about the actual production capacity of the Salt Lake City facility being only 100 drones per month, Red Cat's stock price fell by 8.93% to close at $1.02 per share on July 28, 2023 [8]. - In the first quarter of fiscal year 2025, Red Cat reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing estimates by $1.07 million [9]. - After a report from Kerrisdale Capital alleged that the SRR Contract was worth only $20 million to $25 million, Red Cat's stock price dropped by 21.54% to close at $8.56 per share on January 17, 2025 [12][13]. Group 3: Legal Proceedings - A federal securities class action has been filed against Red Cat, with a deadline of July 21, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Red Cat and its executives made materially false and misleading statements regarding the company's business and operations throughout the class period [4][6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by July 21, 2025 [2][4]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending from open exchanges to closed platforms, where the company's capabilities were limited [4]. - It is claimed that the monetization of DoubleVerify's high-margin Activation Services was hindered due to the expensive and time-consuming development of technology for closed platforms [4]. - The complaint states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, negatively impacting the company's competitive edge and profits [4]. - Allegations include that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and that risk disclosures were materially false and misleading [4]. Group 2: Impact of Allegations - The truth about DoubleVerify's financial struggles was revealed on February 27, 2025, when the company reported lower-than-expected fourth quarter 2024 sales and earnings, leading to a significant stock price drop of $7.83 per share, or 36% [5]. - The stock price fell from a closing price of $21.73 on February 27, 2025, to $13.90 on February 28, 2025, following the disclosure of reduced customer spending and service suspensions [5]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [6]. - Any member of the class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6].

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ibotta, Inc. (NYSE: IBTA).Shareholders who purchased shares of IBTA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ibotta-loss-submission-form/?id=152562&from=4CLASS PERIOD: This lawsuit is on behalf of person ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of Fortrea Holdings, Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2025. SO WHAT: If you purchased Fortrea securities duri ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Vestis To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Vestis between May 2, 2024 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) - ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of Ibotta, Inc. securities about a class action lawsuit related to the company's initial public offering and subsequent performance issues, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Ibotta securities between April 18, 2024, and February 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that Ibotta made false or misleading statements regarding its business operations and financial health, particularly concerning its contract with Kroger and revenue generation [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruq ...

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Red Cat Holdings, Inc. (NASDAQ: RCAT). Shareholders who purchased shares of RCAT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-8903 SOUR ...